A high abundance of tumor infiltrating T cells is a predictive marker of ICI efficacy, and a low number of MDSCs has been shown to correlate with an increased chance of responding to anti-CTLA4 therapy [32, 33]. This evidence concerns the gene CTLA4 and neoplasm.